Phase 3, multicenter, multi-national, randomized, partial double-blind, placebo-controlled study to evaluate the efficacy and safety of alfimeprase in subjects with acute peripheral arterial occlusion.

Next Previous
Trial Profile

Phase 3, multicenter, multi-national, randomized, partial double-blind, placebo-controlled study to evaluate the efficacy and safety of alfimeprase in subjects with acute peripheral arterial occlusion.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Alfimeprase (Primary)
  • Indications Catheter thrombosis; Peripheral arterial occlusive disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms NAPA-2

    • Most Recent Events

    • 01 Mar 2010 Primary endpoint results published in the Journal of Vascular Surgery
    • 12 May 2009 ARCA-biopharma-Inc added as trial sponsor and trial affiliate, lead trial centre aaded as reported by ClinicalTrials.gov.
    • 22 Jan 2008 The expected completion date for this trial is now 1 Feb 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top